Evidence map›Paper›PMID 32158257›Full record

ArticleCancer management and research2020

Cosmc Disruption-Mediated Aberrant O-glycosylation Suppresses Breast Cancer Cell Growth via Impairment of CD44.

Tan Du, Xingyuan Jia, Xichen Dong, Xiaoli Ru, Lina Li, Yakun Wang, Jian Liu, Guosheng Feng, Tao Wen

Open access · goldAbstract read
In one paragraph

Article in Cancer management and research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Glycosylation in kidney diseases.Precision clinical medicine · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tan Du *Department of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.ORCID 0000-0001-6001-703X
Xingyuan Jia *Medical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.
Xichen DongMedical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.ORCID 0000-0003-3282-7929
Xiaoli RuDepartment of Gynecology and Obstetrics Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.ORCID 0000-0003-0876-4526
Lina LiMedical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.ORCID 0000-0003-3481-4574
Yakun WangMedical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.
Jian LiuMedical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.
Guosheng FengDepartment of Oncology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.ORCID 0000-0002-3975-4032
Tao WenMedical Research Center, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020, People's Republic of China.ORCID 0000-0003-0675-0163
Capital Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer remains the most lethal malignancy in women worldwide. Aberrant O-glycosylation is closely related to many human diseases, including breast carcinoma; however, its precise role in cancer development is insufficiently understood. Cosmc is an endoplasmic reticulum-localized chaperone that regulates the O-glycosylation of proteins. Cosmc dysfunction results in inactive T-synthase and expression of truncated O-glycans such as Tn antigen. Here we investigated the impact of Cosmc disruption-mediated aberrant O-glycosylation on breast cancer cell development through in vitro and in vivo experiments. MATERIALS AND

methodsWe deleted the Cosmc gene in two breast cancer cell lines (MCF7, T47D) using the CRISPR/Cas-9 system and then measured the expression levels of Tn antigen. The proliferation of Tn-positive cells was examined by RTCA, colony formation and in vivo experiments. The effects of Cosmc deficiency on glycoprotein CD44 and MAPK pathway were also determined.

resultsBoth in vitro and in vivo studies showed that Cosmc deficiency markedly suppressed breast cancer cell growth compared with the corresponding controls. Mechanistically, Cosmc disruption impaired the protein expression of CD44 and the associated MAPK signaling pathway; the latter plays a crucial role in cell proliferation. Reconstitution of CD44 substantially reversed the observed alterations, confirming that CD44 requires normal O-glycosylation for its proper expression and activation of the related signaling pathway.

conclusionThis study showed that Cosmc deficiency-mediated aberrant O-glycosylation suppressed breast cancer cell growth, which was likely mediated by the impairment of CD44 expression.

Indexed as

breast cancerO-glycosylationTn antigentumor growth

Identifiers

PMID32158257
PMCPMC6986418
OpenAlexW3001454298

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.